phosphatidyl ethanolamine/nausea

Lyen an sove nan clipboard la

AtikEsè klinikPatant

Chwazi kalite sòt

6 rezilta yo

Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) is a synthetic biological investigational agent used for treating osteosarcoma. It has been used in both canine and human osteosarcoma to reduce pulmonary metastases, the most common pattern of treatment failure for sarcomas. L-MTP-PE

Role of phosphatidyl-ethanolamine biosynthesis in herpes simplex virus 1 infected cells on progeny virus morphogenesis in the cytoplasm and on viral pathogenicity in vivo

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Glycerophospholipids are major components of cell membranes. Phosphatidylethanolamine (PE) is a glycerophospholipid and is involved in multiple cellular processes, such as membrane fusion, cell cycle, autophagy and apoptosis. In this study, we investigated the role of PE biosynthesis in herpes

Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The macrophage activator muramyl tripeptide-phosphatidyl ethanolamine (MTP-PE) was infused in liposomal form in 14 metastatic cancer patients (4 mg i.v. during 30 min twice weekly for 12 weeks). Clinical, pharmacokinetic and immunological parameters were studied before and 0.5, 2, 4, 24 and 72h

Novel therapeutic approaches in pediatric and young adult sarcomas.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Novel therapy as part of sarcoma treatment schemas can enhance quality of life and is important in improving outcomes of high-risk sarcomas. Additional chemotherapy and biotherapy options to reduce tumor burden and prevent metastases include intra-arterial chemotherapy in osteosarcoma; intrapleural

A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE This study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), safety/tolerability, and cardiac safety of liposomal muramyl tripeptide phosphatidyl-ethanolamine [mifamurtide (L-MTP-PE)] in healthy adults. METHODS L-MTP-PE 4 mg was administered intravenously over 30 min. Study

Mifamurtide: a review of its use in the treatment of osteosarcoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; Mepact) is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. In the EU, mifamurtide is indicated in children, adolescents, and young adults for the treatment of

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye